Combo effective in cutaneous metastatic melanoma

Therapy with intralesional interleukin 2 and two topical agents results in a 100% complete response rate for cutaneous metastatic melanoma, a retrospective case series analysis suggests.

All eleven US patients, with stage III or IV disease, achieved complete clinical response to the treated lesions within one to three months of initiating interleukin 2 (IL-2) injections into the lesion site.

Two-year survival after